Profile data is unavailable for this security.
About the company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
- Revenue in USD (TTM)10.63m
- Net income in USD-73.50m
- Incorporated2008
- Employees17.00
- LocationCarisma Therapeutics Inc245 1st St Ste 1800CAMBRIDGE 02142-1292United StatesUSA
- Phone+1 (617) 444-8550
- Fax+1 (617) 858-0911
- Websitehttps://sesenbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celularity Inc | 14.79m | -181.41m | 65.78m | 225.00 | -- | 1.93 | -- | 4.45 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
| Cue Biopharma Inc | 5.49m | -50.73m | 66.40m | 53.00 | -- | 1.74 | -- | 12.09 | -1.11 | -1.11 | 0.12 | 0.7855 | 0.0719 | -- | 6.26 | 103,584.90 | -66.40 | -57.45 | -81.71 | -68.41 | -- | -- | -924.10 | -810.87 | -- | -- | 0.1804 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Bioqual Inc | 61.62m | -457.71k | 67.08m | 108.00 | -- | 1.74 | 32.39 | 1.09 | -0.5117 | -0.5117 | 68.90 | 43.10 | 0.9983 | -- | 2.65 | -- | -0.7415 | 8.14 | -0.8392 | 9.52 | 11.13 | 19.36 | -0.7427 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| MDxHealth SA - ADR | -100.00bn | -100.00bn | 67.40m | 258.00 | -- | 9.35 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Elutia Inc | 24.75m | -41.25m | 67.48m | 54.00 | -- | -- | -- | 2.73 | -2.20 | -2.08 | 1.35 | -1.66 | 0.4408 | 1.97 | 4.90 | 458,240.80 | -73.48 | -42.93 | -309.94 | -79.34 | 44.67 | 43.32 | -166.70 | -64.16 | 0.6367 | -3.54 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Carisma Therapeutics Inc | 10.63m | -73.50m | 68.13m | 17.00 | -- | 1.43 | -- | 6.41 | -3.70 | -3.70 | 0.411 | 1.15 | 0.0694 | -- | -- | 625,294.10 | -47.96 | -25.47 | -56.78 | -27.87 | -- | -- | -691.39 | -236.32 | -- | -- | 0.0211 | -- | 50.69 | 148.16 | -5,817.86 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 68.24m | 230.00 | -- | -- | -- | 1.39 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Instil Bio Inc | 0.00 | -156.09m | 68.94m | 49.00 | -- | 0.3053 | -- | -- | -24.00 | -24.00 | 0.00 | 34.72 | 0.00 | -- | -- | 0.00 | -38.65 | -- | -40.84 | -- | -- | -- | -- | -- | -- | -- | 0.265 | -- | -- | -- | 30.06 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -23.52m | 68.98m | 31.00 | -- | 1.49 | -- | -- | -1.96 | -1.96 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -52.09 | -58.43 | -53.82 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| AN2 Therapeutics Inc | 0.00 | -64.73m | 69.07m | 41.00 | -- | 0.5533 | -- | -- | -2.82 | -2.82 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -53.65 | -- | -58.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Assembly Biosciences Inc | 7.16m | -61.23m | 69.36m | 65.00 | -- | 1.69 | -- | 9.68 | -14.02 | -14.02 | 1.63 | 7.50 | 0.06 | -- | 14.51 | 110,200.00 | -51.32 | -39.69 | -66.88 | -44.03 | -- | -- | -854.78 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Landos Biopharma Inc | 0.00 | -21.94m | 69.59m | 19.00 | -- | 2.19 | -- | -- | -3.49 | -3.49 | 0.00 | 10.20 | 0.00 | -- | -- | 0.00 | -52.67 | -59.84 | -61.86 | -72.15 | -- | -- | -- | -795.80 | -- | -516.52 | 0.00 | -- | -- | -- | 44.15 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 69.62m | 12.00 | -- | 4.08 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 70.11m | 2.00 | -- | 10.81 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Carisma Therapeutics Inc's reporting currency: US Dollar USD
16.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.72m | 4.27% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.55m | 3.84% |
| University of Pennsylvania (Investment)as of 31 Dec 2023 | 1.25m | 3.10% |
| Geode Capital Management LLCas of 31 Dec 2023 | 515.89k | 1.28% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 500.31k | 1.24% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 311.03k | 0.77% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 227.05k | 0.56% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 213.03k | 0.53% |
| Teachers Advisors LLCas of 31 Dec 2023 | 86.47k | 0.21% |
| BlackRock Investment Management LLCas of 31 Dec 2023 | 78.39k | 0.19% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
